Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Thomas M. McCloskey"'
Autor:
Yei Mei Peng, Gerald B. Grindey, Marta Hamilton, Thomas M. McCloskey, Charles W. Taylor, Denise J. Roe, David S. Alberts, David E. Seitz, Patricia M. Plezia, Monika Matzner
Publikováno v:
JNCI Journal of the National Cancer Institute. 84:1798-1802
BACKGROUND Sulofenur is a diarylsulfonylurea with demonstrated antitumor activity in patients with advanced epithelial ovarian cancer refractory to standard chemotherapy. The dose-limiting toxic effects observed in phase I clinical trials have been a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b87fad6282ec167686fc205eb1db0f4
https://doi.org/10.1093/jnci/84.23.1798
https://doi.org/10.1093/jnci/84.23.1798
Autor:
Thomas M. McCloskey, Y. M. Peng, William H Kreisle, Martine George, Patricia M. Plezia, David S. Alberts, Alan F. List
Publikováno v:
Europe PubMed Central
Based on clinical evidence that prolonged exposure to anti-neoplastic agents may ameliorate dose-limiting toxicity while facilitating anti-tumor activity, we conducted a phase I trial of 14-day continuous intravenous infusion mitoxantrone. Study obje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb17865bba0f3756bf9b417aedefd749
https://pubmed.ncbi.nlm.nih.gov/1802019
https://pubmed.ncbi.nlm.nih.gov/1802019
Autor:
David S. Alberts, Aurelia Robertone, Patricia M. Plezia, Thomas M. McCloskey, Mark T. Holdsworth, Winston G. Satterlee, Charles W. Taylor, Sydney E. Salmon
Publikováno v:
Investigational new drugs. 8
The semi-synthetic vinca alkaloid vinzolidine was administered to advanced cancer patients as an intravenous bolus on a three day schedule every 21 days. Forty-two patients were treated in this phase I trial. Five partial remissions (breast--1, melan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56bca65a5421bdf2cf42d4675b33b50e
https://pubmed.ncbi.nlm.nih.gov/2380017
https://pubmed.ncbi.nlm.nih.gov/2380017
Autor:
L. Michael Koenig, Thomas M. McCloskey, Robert T. Dorr, Margaret S. Dordal, Charles W. Taylor
Publikováno v:
Cancer. 64:2462-2464
A 56-year-old patient with multiple myeloma experienced an extravasation of doxorubicin (DOX) and vincristine administered as a 96-hour infusion. An unknown quantity of solution (2.1 mg/ml of DOX and 0.1 mg/ml of vincristine) extravasated into the me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eadce02b0261dd4aedd34bcd34b7db8e
https://doi.org/10.1002/1097-0142(19891215)64:12<2462::aid-cncr2820641211>3.0.co
https://doi.org/10.1002/1097-0142(19891215)64:12<2462::aid-cncr2820641211>3.0.co
Autor:
Thomas M. McCloskey, M T Holdsworth, Y. M. Peng, M Hamilton, D.S. Alberts, M A Ketcham, W G Satterlee, Denise J. Roe, Patricia M. Plezia, Charles W. Taylor
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 7(11)
LY186641 (diarylsulfonylurea, [DSU]) is a novel anticancer agent because of its unique diarylsulfonylurea chemical structure, broad-spectrum antisolid-tumor activity in preclinical models, presumed novel mechanism of action and preclinical toxicities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baad62c74e896a1cbaba3ce30230f808
https://pubmed.ncbi.nlm.nih.gov/2809686
https://pubmed.ncbi.nlm.nih.gov/2809686